In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on Tc-99(m)-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination

Papathomas T, Tzortzakakis A, Sun N, Erlmeier F, Feuchtinger A, Trpkov K, Bazarova A, Arvanitis A, Wang W, Bozoky B, Kokaraki G, Axelsson R, Walch A (2020)

Publication Type: Journal article

Publication year: 2020

Journal

European Urology Open Science Elsevier

Book Volume: 22

Pages Range: 88-96

DOI: 10.1016/j.euros.2020.11.001

Abstract

Background: Definite noninvasive characterisation of renal tumours positive on Tc-99m-sestamibi single photon emission computed tomography/computed tomography (SPECT/CT) examination including renal oncocytomas (ROs), hybrid oncocytic chromophobe tumours (HOCTs), and chromophobe renal cell carcinoma (chRCC) is currently not feasible.

Authors with CRIS profile

Franziska Erlmeier Institute of Pathology

Involved external institutions

Karolinska University Hospital / Karolinska Universitetssjukhuset SE Sweden (SE) Karolinska Institute SE Sweden (SE) Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (HMGU) / Helmholtz Munich DE Germany (DE) University of Birmingham GB United Kingdom (GB) University of Calgary CA Canada (CA) Universität zu Köln DE Germany (DE)

How to cite

APA:

Papathomas, T., Tzortzakakis, A., Sun, N., Erlmeier, F., Feuchtinger, A., Trpkov, K.,... Walch, A. (2020). In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on Tc-99(m)-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination. European Urology Open Science, 22, 88-96. https://doi.org/10.1016/j.euros.2020.11.001

MLA:

Papathomas, Thomas, et al. "In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on Tc-99(m)-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination." European Urology Open Science 22 (2020): 88-96.

BibTeX: Download